{"id":8633,"date":"2020-03-06T16:34:50","date_gmt":"2020-03-06T11:04:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8633"},"modified":"2024-09-17T16:50:09","modified_gmt":"2024-09-17T11:20:09","slug":"soft-tissue-sarcoma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma","title":{"rendered":"Soft Tissue Sarcoma: A rare malignancy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f797376cc88\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f797376cc88\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Soft_Tissue_Sarcoma_Epidemiology\" >Soft Tissue Sarcoma Epidemiology<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Gender-specific_STS_epidemiology\" >Gender-specific STS epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Type-specific_STS_Epidemiology\" >Type-specific STS Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Age-specific_Soft_tissue_Sarcoma_Epidemiology\" >Age-specific Soft tissue Sarcoma Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Stage-specific_Soft_tissue_Sarcoma_Epidemiology\" >Stage-specific Soft tissue Sarcoma Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Extremity-specific_Soft_tissue_Sarcoma_Epidemiology\" >Extremity-specific Soft tissue Sarcoma Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\/#Soft_tissue_Sarcoma_Treatment_approaches\" >Soft tissue Sarcoma Treatment approaches<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p>What does a yellow ribbon signify? It symbolizes support for Sarcoma patients. Sarcoma \u2013 an umbrella term for several forms of cancer that occur in muscles or bones \u2013 is a rare form of cancer. There exist more than 70 types of sarcomas \u2013 mostly considered rare \u2013 classified on the basis of the type of tissue they affect, broadly categorized as soft tissue sarcoma and bone sarcoma.&nbsp;<\/p>\n\n\n\n<p>However, Soft tissue sarcoma (STS) is the most frequently occurring sarcomas of all. Invading connective tissue such as muscles, fatty tissues, bones, cartilage, and blood vessels, Soft tissue sarcoma, a rare sarcoma \u2013 is often difficult to diagnose, notable due to no visible symptoms at early stages. However, with an increase in the propensity of cancer, the patient begins to experience pain and a lump of mass at the origin of the soft tissue sarcoma. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Soft_Tissue_Sarcoma_Epidemiology\"><\/span><strong>Soft Tissue Sarcoma Epidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p> In the year 2017, the total<a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-market\"> Soft tissue sarcoma incident population<\/a> in the 7MM was observed to be approximately 40,155 \u2013 estimated DelveInsight. Moreover, the US accounted for the maximum number of STS incidence case, followed by Germany, with Spain accounting for least Soft tissue sarcoma incidence.  <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gender-specific_STS_epidemiology\"><\/span><strong>Gender-specific STS epidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p> Accounting for less than 1-2 % of all the cancers, Soft tissue sarcoma is deadly cancer with a predominant preponderance in males as compared to in females, with a total of 9,925 male and 7,555 female Soft tissue sarcoma diagnosed cases in 2017 in the United States, as observed by DelveInsight.  <\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-market\"><img decoding=\"async\" src=\"https:\/\/lh6.googleusercontent.com\/fEydXA1mn85ieIZuAidrQMPQek_wAaKr97DhAACivQMVbAKBh5LtcLlo3QbenrVejIYvD34YoDzUurCEKY3fWyo7AFliJ46qoJPJZKu-tJ3LC2NVwOs20jH-yDahUstWOIhM4mCOiohjNoyuYQ\" alt=\" Gender-specific STS epidemiology  \" width=\"401\" height=\"190\"\/><\/a><figcaption><strong> Gender-specific STS epidemiology&nbsp;<\/strong> <\/figcaption><\/figure><\/div>\n\n\n\n<p> Moreover, estimates by the <em>American Cancer Society<\/em> revealed around 13,130 new diagnosed cases for 2020 (7,470 in males and 5,660 in females), and 5,350 deaths (2,870 males and 2,480 females) due to soft tissue sarcoma.   <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Type-specific_STS_Epidemiology\"><\/span><strong>Type-specific STS Epidemiology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In terms of types of Soft tissue sarcoma, in the United States, there were 2,961 cases of Leiomyosarcoma, followed by Fibroblastic sarcomas, LPS, and synovial sarcoma. Among the above-mentioned types, epithelioid sarcoma and clear cell sarcoma has the least number of the patient pool, i.e., 0.50%, of the overall STS patients in the country in 2017.  <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Age-specific_Soft_tissue_Sarcoma_Epidemiology\"><\/span><strong>Age-specific Soft tissue Sarcoma Epidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p> As per DelveInsight\u2019s analysis, a maximum number of cases were of age 55 or older in 2017. <a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-market\">Soft tissue sarcoma patients<\/a> ranging from age group 21 to 54 years were reported to be the second-highest.  <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Stage-specific_Soft_tissue_Sarcoma_Epidemiology\"><\/span><strong>Stage-specific Soft tissue Sarcoma Epidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>According to DelveInsight\u2019s analysts, localized soft tissue sarcoma accounted for almost 60% of the overall STS cases in 2017. In the US, there were 7,434 cases of localized type, 2,354 cases of regional type, 1,859 cases of regional type, and 743 cases of an unknown type of soft tissue sarcoma, estimated DelveInsight.&nbsp;<\/p>\n\n\n\n<p>Moreover, as per the analysis done by SEER for the period of 2009-15, 81% of the people diagnosed with localized soft tissue sarcoma had 5-year relative survival rate. On the other hand, the rate with regional, and distant STS was 57% and 16% respectively. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Extremity-specific_Soft_tissue_Sarcoma_Epidemiology\"><\/span><strong>Extremity-specific Soft tissue Sarcoma Epidemiology <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Soft tissue sarcoma on the basis of extremities \u2013 upper and lower \u2013 accounted for 5,699 and 1,859 cases respectively in the US in 2017.<\/p>\n\n\n\n<p>DelveInsight estimates that Increasing Soft tissue sarcoma incidence would certainly fuel the Soft tissue sarcoma therapy market, as the current STS therapies are palliative in nature. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Soft_tissue_Sarcoma_Treatment_approaches\"><\/span><strong>Soft tissue Sarcoma Treatment approaches <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rare, and heterogenous, Soft tissue sarcomas are relatively hard to diagnose cane be treated via surgery, chemotherapy, radiation therapy, or a combination of these therapies. Moreover, Soft tissue sarcoma treatment options for patients with advanced STS have historically been limited; cytotoxic chemotherapy has been the mainstay of therapy for decades. Active drugs include <strong>doxorubicin<\/strong>, ifosfamide, <strong>gemcitabine<\/strong>, <strong>taxanes<\/strong>, and several others; these may be administered either as single agents or in combination regimens.&nbsp;<\/p>\n\n\n\n<p>Combination therapy of <strong>doxorubicin<\/strong> and <strong>ifosfamideis<\/strong> is the most commonly administered regimen. The combination has shown significantly a higher rate of objective response induction as compared to single-agent doxorubicin,<\/p>\n\n\n\n<p>The most commonly used regimen is the combination of doxorubicin and ifosfamide. From randomized trials performed in the advanced\/metastatic setting of soft tissue sarcoma, such a combination is known to be associated with a significantly higher rate of objective response induction as compared to single-agent doxorubicin.&nbsp;<\/p>\n\n\n\n<p>Whichever therapy is present in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-pipeline-insight\">Soft tissue sarcoma therapy market<\/a>, they are palliative in nature. However, past years have witnessed a surge in the clinical trials and therapy approaches revolving around chemotherapy, and newer agents including <strong>olaratumab<\/strong>, <strong>trabectedin<\/strong>, <strong>pazopanib,<\/strong> which have suggested that such an approach would down-size the tumor in the preoperative setting, improving overall survival. The intent of these treatments is palliative for the majority of patients.&nbsp;The FDA approval of <strong>Votrient<\/strong> (pazopanib) in 2012 for second-line treatment of advanced soft tissue sarcoma gave a kick start to soft tissue sarcoma treatment market, encouraging other pharma and biotech companies to advance Soft tissue sarcoma therapy market.&nbsp; <a href=\"https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape\">Key Soft tissue sarcoma companies <\/a>working in the field including Eli Lilly, Novartis, GSK, Bayer, Blueprint Medicines Corporation, Advenchen Laboratories\/Jiangsu Chia-Tai Tianqing Pharmaceutical, Karyopharm Therapeutics, Deciphera Pharmaceuticals, Philogen, Epizyme, Pfizer, Aadi Bioscience, and many others are developing novel therapies to treat soft tissue sarcoma.  <\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>What does a yellow ribbon signify? It symbolizes support for Sarcoma patients. Sarcoma \u2013 an umbrella term for several forms of cancer that occur in muscles or bones \u2013 is a rare form of cancer. There exist more than 70 types of sarcomas \u2013 mostly considered rare \u2013 classified on the basis of the type [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17,17434],"tags":[18110,18100,107,18105,18108,228,1867,18102,18098,903,18107,423,460,18109,11601,11602,11604,11605,18104,11603,18103,18101,18099],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-8633","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-facts-and-figures","tag-aadi-bioscience","tag-age-specific-soft-tissue-sarcoma-epidemiology","tag-bayer","tag-blueprint-medicines-corporation","tag-deciphera-pharmaceuticals","tag-eli-lilly","tag-epizyme","tag-extremity-specific-soft-tissue-sarcoma-epidemiology","tag-gender-specific-sts-epidemiology","tag-gsk","tag-karyopharm-therapeutics","tag-novartis","tag-pfizer","tag-philogen","tag-soft-tissue-sarcoma","tag-soft-tissue-sarcoma-epidemiology","tag-soft-tissue-sarcoma-epidemiology-drug","tag-soft-tissue-sarcoma-epidemiology-market","tag-soft-tissue-sarcoma-therapy-market","tag-soft-tissue-sarcoma-treatment","tag-soft-tissue-sarcoma-treatment-approaches","tag-stage-specific-soft-tissue-sarcoma-epidemiology","tag-type-specific-sts-epidemiology","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Soft Tissue Sarcoma Epidemiology | DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"In the year 2017, the total Soft tissue sarcoma incident population in the 7 major markets was observed to be approximately 40,155.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soft Tissue Sarcoma Epidemiology | DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"In the year 2017, the total Soft tissue sarcoma incident population in the 7 major markets was observed to be approximately 40,155.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-06T11:04:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:20:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/06163057\/slide6.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Soft Tissue Sarcoma Epidemiology | DelveInsight Business Research","description":"In the year 2017, the total Soft tissue sarcoma incident population in the 7 major markets was observed to be approximately 40,155.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma","og_locale":"en_US","og_type":"article","og_title":"Soft Tissue Sarcoma Epidemiology | DelveInsight Business Research","og_description":"In the year 2017, the total Soft tissue sarcoma incident population in the 7 major markets was observed to be approximately 40,155.","og_url":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-06T11:04:50+00:00","article_modified_time":"2024-09-17T11:20:09+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/06163057\/slide6.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma","url":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma","name":"Soft Tissue Sarcoma Epidemiology | DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/06163057\/slide6.jpg","datePublished":"2020-03-06T11:04:50+00:00","dateModified":"2024-09-17T11:20:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"In the year 2017, the total Soft tissue sarcoma incident population in the 7 major markets was observed to be approximately 40,155.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/soft-tissue-sarcoma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/06163057\/slide6.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/06163057\/slide6.jpg","width":772,"height":482,"caption":"Soft Tissue Sarcoma"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/06163057\/slide6-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Facts and Figures<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>","<span class=\"advgb-post-tax-term\">Facts and Figures<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Aadi Bioscience<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Age Specific Soft tissue Sarcoma Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Blueprint Medicines Corporation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Deciphera Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Epizyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Extremity Specific Soft tissue Sarcoma Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Gender Specific STS Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Karyopharm Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Philogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft tissue Sarcoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft tissue Sarcoma Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft tissue Sarcoma Epidemiology drug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft tissue Sarcoma Epidemiology market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft Tissue Sarcoma Therapy Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft tissue Sarcoma treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Soft Tissue Sarcoma Treatment Approaches<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Stage Specific Soft tissue Sarcoma Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/facts-and-figures\/\" class=\"advgb-post-tax-term\">Type Specific STS Epidemiology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aadi Bioscience<\/span>","<span class=\"advgb-post-tax-term\">Age Specific Soft tissue Sarcoma Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Blueprint Medicines Corporation<\/span>","<span class=\"advgb-post-tax-term\">Deciphera Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Epizyme<\/span>","<span class=\"advgb-post-tax-term\">Extremity Specific Soft tissue Sarcoma Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Gender Specific STS Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Karyopharm Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Philogen<\/span>","<span class=\"advgb-post-tax-term\">Soft tissue Sarcoma<\/span>","<span class=\"advgb-post-tax-term\">Soft tissue Sarcoma Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Soft tissue Sarcoma Epidemiology drug<\/span>","<span class=\"advgb-post-tax-term\">Soft tissue Sarcoma Epidemiology market<\/span>","<span class=\"advgb-post-tax-term\">Soft Tissue Sarcoma Therapy Market<\/span>","<span class=\"advgb-post-tax-term\">Soft tissue Sarcoma treatment<\/span>","<span class=\"advgb-post-tax-term\">Soft Tissue Sarcoma Treatment Approaches<\/span>","<span class=\"advgb-post-tax-term\">Stage Specific Soft tissue Sarcoma Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Type Specific STS Epidemiology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Mar 6, 2020","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Mar 6, 2020 4:34 pm","modified":"Updated on Sep 17, 2024 4:50 pm"},"featured_img_caption":"Soft Tissue Sarcoma","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8633"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8633\/revisions"}],"predecessor-version":[{"id":29566,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8633\/revisions\/29566"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8641"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8633"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8633"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}